ABSTRACT
Background Advanced Head and Neck Squamous Cell Cancer (HNSCC) is associated with a poor prognosis, and biomarkers that predict response to treatment are highly desirable. The primary aim was to predict Progression Free Survival (PFS) with a multivariate risk prediction model.
Methods Blood samples from 56 HNSCC patients were prospectively obtained within a Phase 2 clinical trial (NCT02633800), before and after the first treatment cycle of platinum-based chemotherapy, to identify biological covariates predictive of outcome. A total of 42 baseline covariates were derived pre-treatment, which were combined with 29 covariates after one cycle of treatment. These covariates were ranked and selected by Bayesian multivariate regression to form risk scores to predict PFS, producing “baseline” and “combined” risk prediction models respectively.
Results The baseline model comprised of CD33+CD14+ monocytes, Double Negative B cells and age, in a weighted risk signature which predicted PFS with a concordance index (C-index) of 0.661. The combined model composed of baseline CD33+CD14+ monocytes, baseline Tregs, after-treatment changes in CD8 effector memory T cells, CD8 Central memory T cells and CD3 T Cells, along with the hypopharyngeal primary tumor subsite. This weighted risk signature exhibited an improved C-index of 0.757. There was concordance between levels of CD33+CD14+ myeloid cells in tumor tissue, as demonstrated by imaging mass cytometry, and peripheral blood in the same patients. This monocyte subpopulation also had univariate predictive value (log-rank p value = 0.03) but the C-index was inferior to the combined signature.
Conclusions This immune-based combined multimodality signature, obtained through longitudinal peripheral blood monitoring, presents a novel means of predicting response early on during the treatment course.
Funding Daiichi Sankyo Inc, Cancer Research UK, EU IMI2 IMMUCAN, UK Medical Research Council, European Research Council (335326), National Institute for Health Research and The Institute of Cancer Research.
Competing Interest Statement
KN has received honoraria from Pfizer, GSK/Tesaro and Boheringer Ingleheim, and has had travel/accommodation/expenses paid for by Tesaro. MDF has received institutional research funding from AstraZeneca, Boehringer-Ingelheim, Merck and MSD and serves in a consulting or advisory role to Achilles, Astrazeneca, Bayer, Bristol-Myers Squibb, Celgene, Guardant Health, Merck, MSD, Nanobiotix, Novartis, Oxford VacMedix, Pfizer, Roche, Takeda, UltraHuman. KH has received honoraria from Amgen; Arch Oncology; AstraZeneca; Boehringer-Ingelheim; Bristol Myers Squibb; Codiak; Inzen; Merck; MSD; Pfizer; Replimune and is on a speakers' bureau for Amgen, AstraZeneca; Bristol-Myers Squibb; Merck, MSD; Pfizer. KH has also received research funding from AstraZeneca, Boehringer-Ingelheim, MSD and Replimune. JG and JD are both in employment with Daiichi Sankyo, and have stock and other ownership interests, research funding within Daichii Sanyko and have had travel/accommodation/expenses paid for by Daichii Sankyo. In addition, JD has also had stock and other ownership interests with Pfizer and received research funding from Novartis. ACCC has stock and other ownership interests with Saddle Point Science Limited. FW was initially funded by Daichii Sankyo as research assistant to conduct laboratory work in the context of the translational aspect of this trial. SK has received research funding in the form of a grant from Novartis and Celgene. TN has received research funding from Astrazeneca and Daichii Sankyo. TN is a founder and shareholder in Nano Clinical Ltd, and PRB is a shareholder. FF-B,GA, GW,JMV,MG,JWO,JB and RM declare no conflicts of interests. The funders had no role in the study design, the collection, analysis and interpretation of the data, 535 the writing of the manuscript, and the decision to publish.
Clinical Trial
NCT02633800
Funding Statement
This work was supported by a grant from Daiichi Sankyo Inc ('Identification of Non-Invasive Treatment Stratification and Longitudinal Monitoring Markers for Patritumab/Cetuximab Combination Therapy'). This work was also supported by Cancer Research UK funding support to King's College London - UCL Comprehensive Cancer Imaging Centre (CR-UK & EPSRC), Cancer Research UK King's Health Partners Centre at King's College London, and Cancer Research UK UCL Centre; University College London (PRB) - Early Detection Award (C7675/A29313); as well as CRUK City of London Centre. MG and KN are supported by Cancer Research UK Clinical Training Fellowships (Award number 163011 for MG and 176885 for KN). LD is supported by EU IMI2 IMMUCAN (Grant agreement number 821558). GA and JMV are supported by CRUK Early Detection and Diagnosis Committee Project grant. JWO is supported by the UK Medical Research Council (MR/N013700/1) and is a KCL member of the MRC Doctoral Training Partnership in Biomedical Science. FW is also supported by the UK Medical Research Council (MR/N013700/1). JNA is funded by a grant from the European Research Council (335326). MDF is supported by the UCL/UCLH NIHR Biomedical Research Centre and runs early phase studies in the NIHR UCLH Clinical Research Facility supported by the UCL ECMC. MTD and KH acknowledge funding support from The Institute of Cancer Research/Royal Marsden Hospital NIHR Biomedical Research Centre. This research was funded/supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London and/or the NIHR Clinical Research Facility. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
NHS HRA Research Ethics Committee reference: 15/LO/1670
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data generated in this study and used for multivariate modelling are available from the UCL repository: https://doi.org/10.5522/04/16566207.v1
List of abbreviations
- C1 or C2
- Timepoint before cycle 1 or cycle 2 of treatment
- C-index
- Harrell’s Concordance Index
- CT
- Computed Tomography
- CyTOF
- Mass Cytometry
- ddPCR
- Digital Droplet Polymerase Chain Reaction
- DN
- Double-Negative
- EGFR
- Epidermal Growth Factor Receptor
- FLIM
- Fluorescence Lifetime Imaging Microscopy
- FRET
- Förster Resonance Energy Transfer
- HPV
- Human Papilloma Virus
- HNSCC
- Head and Neck Squamous Cell Cancer
- HR
- Hazard Ratio
- KM
- Kaplan-Meier
- LFC
- Log Fold Change
- miRNA
- Micro-RNA
- PBMC
- Peripheral Blood Mononuclear Cells
- PCR
- Polymerase Chain Reaction
- PFS
- Progression Free Survival
- Tregs
- Regulatory T cells
